Skip to content
10-Q

Quarterly Report

INNOVATION PHARMACEUTICALS INC.

0001477932-23-008688

← back to feed
Filed
Nov 20, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2024 · Sep 30, 2023 −$677K
Operating Cash Flow Q1 2024 · Sep 30, 2022 −$791K
Cash And Equivalents Q1 2024 · Sep 30, 2023 $864K
Cash And Equivalents Q1 2024 · Jun 30, 2023 $1.52M
Stockholders Equity Q1 2024 · Sep 30, 2023 $1.16M
Stockholders Equity Q1 2024 · Jun 30, 2023 $2.04M
Stockholders Equity Q1 2024 · Sep 30, 2022 $3.42M
Stockholders Equity Q1 2024 · Jun 30, 2022 $4.73M
Current Liabilities Q1 2024 · Sep 30, 2023 $5.05M
Current Liabilities Q1 2024 · Jun 30, 2023 $5.02M
Total Liabilities Q1 2024 · Sep 30, 2023 $5.51M
Total Liabilities Q1 2024 · Jun 30, 2023 $5.48M
Current Assets Q1 2024 · Sep 30, 2023 $940K
Current Assets Q1 2024 · Jun 30, 2023 $1.63M
Total Assets Q1 2024 · Sep 30, 2023 $6.67M
Total Assets Q1 2024 · Jun 30, 2023 $7.52M
Sga Expense Q1 2024 · Sep 30, 2023 $133K
Sga Expense Q1 2024 · Sep 30, 2022 $291K
Rd Expense Q1 2024 · Sep 30, 2023 $281K
Rd Expense Q1 2024 · Sep 30, 2022 $869K
Net Income Q1 2024 · Sep 30, 2023 −$880K
Net Income Q1 2024 · Sep 30, 2022 −$1.43M
Operating Income Q1 2024 · Sep 30, 2023 −$866K
Operating Income Q1 2024 · Sep 30, 2022 −$1.41M
Revenue Q1 2024 · Sep 30, 2023 $0
Revenue Q1 2024 · Sep 30, 2022 $0